Ampersand snags $50M as Flagship focuses therapeutics on desired targets only

Kyle LaHucik

Senior Reporter

The behemoth biotech creator Flagship Pioneering is out with another startup aiming to achieve the crown jewel of drug development: treatments that hit only the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ampersand snags $50M as Flagship focuses therapeutics on desired targets only

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

ADCs from a decade-old Singapore biotech find new life with $187M

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Am­per­sand snags $50M as Flag­ship fo­cus­es ther­a­peu­tics on de­sired tar­gets on­ly

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ampersand snags $50M as Flagship focuses therapeutics on desired targets only